| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Adlai Nortye | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Amylyx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $203.25M | Series C-1 | 7/20/2021 | $107.33M | $541.01M | $10.27 | Viking Global Investors, Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund, Falcon Edge, Morningside Ventures, 683 Capital Management, Belinda Termeer, Polaris Founders Capital | ||||
 | Attovia | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.85M | Series C | 4/15/2025 | $90M | $368.16M | $12.77 | Deep Track Capital, Vida Ventures, Sanofi Ventures, Mirae Asset Capital Life Science, Frazier Life Sciences, venBio, Goldman Sachs, Nextech Ventures, Cormorant Asset Management, EcoR1 Capital, Marshall Wace, Illumina Ventures | ||||
 | BioAge | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.42B | Series D | 2/13/2024 | $170M | $440.23M | $3.42 | Sofinnova Investments, Longitude Capital, RA Capital, Cormorant Asset Management, RTW Investments, SV Health Investors, OrbiMed Advisors, Sands Capital, Pivotal bioVenture Partners, Osage University Partners, Lilly Ventures, Amgen Ventures, Andreessen Horowitz | ||||
 | Codiak BioSciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $168.37M | Series C | 11/29/2017 | $76.37M | $404.14M | $3.78 | ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund, Alexandria Venture Investments | ||||
 | Entrada Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $204.63M | Series B | 3/31/2021 | $116.25M | $360.98M | $15.72 | Wellington Management, Redmile Group, TCG Crossover, Greenspring Associates, Point72, Qatar Investment Authority, Moore Strategic Ventures, Goldman Sachs, CureDuchenne Ventures, 5AM Ventures, MPM Capital, Roche Venture Fund, MSD, Agent Capital | ||||
 | MapLight Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $511M | Series D | 9/30/2025 | $200M | $883.21M | $0.95 | Catalyst4, Forbion, Sanofi, Novo Holdings | ||||
 | Revolution Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Seaport Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $330.1M | Series B | 10/21/2024 | $226M | $725.46M | $14.92 | General Atlantic, T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs, CPP Investments, ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, PureTech Health | ||||
 | Seer | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Spyglass Pharma | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $200.88M | Series D | 6/2/2025 | $77.33M | $363.51M | $13.33 | Sands Capital, Gilde Healthcare, New Enterprise Associates, RA Capital Management, Censana Capital, Samsara BioCapital, Vertex Ventures HC | ||||
 | Aardvark Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $129.13M | Series C | 5/9/2024 | $85M | $267.58M | $1.77 | Decheng Capital, Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Ventures, Silver Arc Private Capital, Prader-Willi Syndrome Association, Vickers Venture Partners, Foundation for Prader-Willi Research | ||||
 | Accolade | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Adaptive Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $561.37M | Series F-1 | 1/4/2018 | $45M | $1.35B | $10.67 | Microsoft | ||||
 | Bolt Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Broncus Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | CAMP4 | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $113.77M | Series B | 7/20/2022 | $100.54M | $297.52M | $1.47 | Patient Square Capital, Gaingels, 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, The Kraft Group | ||||
 | Contineum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $133.61M | Series C | 2/11/2021 | $80.4M | $244.63M | $2.68 | Perceptive Advisors, Franklin Templeton, Casdin Capital, Samsara BioCapital, Suvretta Capital, Red Tree Venture Capital, Versant Ventures, Sectoral Asset Management, Cleva Pharma | ||||
 | Scribe Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $120.71M | Series B | 3/31/2021 | $100M | $351.77M | $35.83 | Avoro Ventures, Avoro Capital Advisors, OrbiMed, Andreessen Horowitz, Perceptive Advisors, T. Rowe Price, Wellington Management, RA Capital Management, Menlo Venture | ||||
 | Tyra Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $157.64M | Series B | 3/31/2021 | $106.3M | $348.37M | $27.43 | Nextech Invest, Cormorant Asset Management, BVF Partners, Janus Henderson Investors, Logos, Alta Partners, RA Capital, Boxer Capital, Cannaan | ||||
 | 4D Molecular Therapeutics (4DMT) | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | 908 Devices | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Annexon Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | IsoPlexis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $161.52M | Series D | 1/7/2021 | $92.5M | $348.21M | $76.92 | Perceptive Advisors, Ally Bridge Group, BlackRock | ||||